### DLRC

Strategic Expertise Operational Excellence Advancing Healthcare

DLRC is a dedicated team of highly qualified and experienced Regulatory Affairs professionals.

hello@dlrcgroup.com <u>www.dlrcgroup.com</u>







### **Meet Our Speakers**



### **James Biddlecombe Business Transformation and CTR Lead** DLRC Ltd, DLRC Group

James's journey with the EU CTR started in 2017, working at the EMA in the CTIS business team. Over the last six years, he supported the development of the regulation and guidance and the development of CTIS and has supported clients with CTR readiness and CTA submissions. He has supported numerous clients in getting them ready for the CTR Go-Live through training, redesign of operating models, and updates to processes and procedures. More recently, he supports clients with strategic direction for trials submitted under the CTR and helps to navigate EU CTR guidelines and ensure CTA document compliance with the regulation.



Wafa is a global regulatory professional with a broad experience across various therapeutic areas including rheumatology, anti-infective, dermatology and oncology. With her strong scientific, regulatory, and managerial expertise, she successfully led early development projects (CTA and IND submissions) and full development programs (MAA and NDA/BLA). She has supported clients with several investigational products through their European regulatory journey, advising on CTA requirements from a strategic perspective. She also acts as the EU legal representative under CTR and helps companies ensure compliance with the new regulation.

**Contact James** 

Connect with James on LinkedIn

Contact Wafa

Confidential | DLRC Group



### Wafa Bouaziz Managing Director & Head of Regulatory Affairs, Orphix Consulting GmbH, DLRC Group

Connect with Wafa on LinkedIn

## Today's Agenda

CTR in the EU Regulatory Landscape	01	Managi
CTR Foundations	02	EU CTR
Spotlight on the role of the EU Legal Rep	03	
CTR & its impact on trial design	04	




### ging CTD to CTR transition

R transparency


05



# What do you really need to know about CTR and related legislation?



## CTR in the current EU Regulatory Landscape



Confidential | DLRC Group



Directive 2002/98/EC of the European Parliament and of the Council

Directive 2001/18/EC of the European Parliament and of the Council

Directive 2009/41/EC of the European Parliament and of the Council

Directive 2010/53/EC of the European Parliament and of the Council

Council Directive 96/29/Euratom

Directive 2004/23/EC of the European Parliament and of the Council

Council Directive 97/43/Euratom

### GMP (EU) 2017/1569

Paediatric Regulation (EC No 1901/2006)

# Can you summarise the new EU Clinical Trial Regulation, on one slide?

2

We will certainly give it a try...

### Aim and Targeted Outcomes

- 1. Ensure high standard of safety and efficacy for trial subjects
- 2. Harmonize the process of conducting clinical trials across the EU.
- 3. Facilitate cross-border collaboration in research
- 4. Promotes transparency and accountability.


## CTR Summarised

### Challenges

- 1. Implementation complexities
- 2. Compliance with new requirements
- 3. Stakeholder adjustments

Confidential | DLRC Group





High Risk – RFI response times:


10 calendar days (validation)

12 calendar days (assessment)


Before you can submit...

- 1. Establish your EU Legal Representative
- 2. Register the Sponsor in EudraVigilance
- 3. Register the Sponsor in OMS (SPOR)
- 4. Register the IMP(s) / AxMP(s) in xEVMPD

# What do you really need to know about CTR impact on clinical trial and EU development strategy, Compliance and Best Practices?



# How does CTR impact trial design and clinical development strategy?



Confidential | DLRC Group




Protocol Harmonisation and Transition

Transparency

CTR Ready & CTA Approval

### Spotlight: What do you really need to know about the role of the EU Legal Representative? Monitoring Patient Protocol and Safety Involvement Harmonisation Reporting Quality and Transition Control and Data Integrity Transparency Legal Representation & Compliance **Trial Design** and CTA Strategy CTR Ready & Scientific Paediatric CTA Regulation Advice Approval



Confidential | DLRC Group

DLRC

## Things have changed. What is the responsibility of the EU legal representative under CTR?

### CTD (2001/20/EC) - Article 19:

"....the sponsor or a legal representative of the sponsor must be established in the Community....." "Where the sponsor of a clinical trial is not established in the Union, that sponsor shall ensure that **a natural or legal person** is established in the Union as its legal representative. Such legal representative shall **be responsible for ensuring compliance with the sponsor's obligations pursuant to this Regulation and shall be the addressee for all communications with the sponsor provided for in this Regulation.** Any communication to that legal representative shall be deemed to be a communication to the sponsor."

Confidential | DLRC Group



### CTR (536/2014) – Article 74:

## Our experience as a legal representative and how to not make mistakes that may cost you time


Common shortcomings that we have experienced when conducting Compliance Gap Analysis:

- Lack of clarity about the end-to-end responsibilities of various business partners involved in the planned trial.
- Insufficient evidence that Sponsor or its CRO's standard operating procedures cover all the necessary Sponsor's trial related duties under the GCP and the CTR (data protection, redactions, study milestone) notifications, result preparation and posting etc.).
- Insurance certificates do not always cover the legal representative

> Under the CTR, the EU legal representative becomes an additional safeguard for CTR and GCP adherence and is an integral part of the sponsor's compliance strategy and best practices



# What do you really need to know about Quality Control and Data Integrity?






# **Quality Control and Data Integrity**

"The reliability and robustness of the data generated in the clinical trial" is mentioned multiple times in the regulation!




### How to effectively ensure "the reliability and robustness of the data generated in the clinical trial"?





**Expected impact:** Rigorous data collection procedures and controls are needed when setting up a trial to meet regulatory requirements

# What do you really need to know about Patient Involvement?



Confidential | DLRC Group



Protocol Harmonisation and Transition

Transparency


CTR Ready & CTA Approval

## Patient Involvement

The regulation emphasises the importance of patient involvement in the design, conduct, and evaluation of clinical trials



### How to efficiently involve patients and promote their engagement?






**Expected impact:** 1) promoting inclusion of patientreported outcomes, 2) enhancing participant recruitment and retention strategies, and 3) improving overall trial relevance and feasibility.

Additional strategic considerations

Patient centred approach
Use of PROs and clinically relevant endpoints
Fit for Purpose Protocol
Builds for the JCA and HTA assessment

# What do you really need to know about Patient Monitoring and Safety Reporting?



Confidential | DLRC Group



Protocol Harmonisation and Transition

Transparency

CTR Ready & CTA Approval

## **Patient Monitoring**

Rigorous safety monitoring procedures to meet regulatory requirements (Article 48)



CTR and GCP Provisions

- Frequency and Intensity of Monitoring a risk-based approach focusing on safety and data integrity
- Remote Monitoring Technologies use of electronic data capture systems and centralized monitoring
- Patient-Centric Approaches facilitate patient engagement and input

Resource intensive if a risk-based approach is not appropriately used




**Expected impact:** Promoting of risk-based approaches, leveraging remote monitoring technologies and adopting patient-centric approaches.

# ased approach focusing on Fonic data capture systems

# Safety Reporting

CTR puts greater emphasis on patient safety within various procedures



### CTR Provisions (Annex III)

- Safety Monitoring Plan
- Risk Assessment
- Safety Reporting Timelines
- Safety Monitoring Committees
- Protocol Modifications


Ensure your QMS captures all new reporting requirements and that responsibilities are clearly identified

Confidential | DLRC Group



**Expected impact:** Promoting proactive risk assessment, timely safety reporting, and appropriate risk mitigation strategies throughout the clinical trial lifecycle.

# What do you really need to know about Protocol harmonization and CTD to CTR transition?



Confidential | DLRC Group



# CTD to CTR transition...tick tock, you're on the clock!

We break down a CTD to CTR transition into three distinct 'stages' to help with understanding

### **Stage 1 – Pre-Transition** activities

- Harmonise / Consolidate protocol
- Prepare 'minimum' dossier
- Register in EMA systems
- Approve EU Legal Rep


The authorisation in Stage 2 must be completed before end of January 2025

### Stage 2 – Application in CTIS

- Expedited review timeline
- Requests for Information •

Confidential | DLRC Group





# What do you really need to know about EU CTR transparency?



Confidential | DLRC Group



# **EU CTR Transparency**

Our best advice is take advantage of the revised transparency rules **now**!

### **Throughout 2023**

ACT EU surveys to industry representatives on the EU **CTR transparency rules** 

### From December 2023

New transparency rules can be applied to initial CTAs under the CTR

### In practice, this means that:


- Fewer documents are subject to publication; it's now a 'patient focus'
- The deferral mechanism is removed
- RFI responses are never published be careful of this before the CTIS update in 2024





CTIS updated to reflect the revised EU CTR transparency rules

## Any questions?



# Can we summarise the overall impact of CTR on EU clinical development strategy, on one slide?

We think we have got this one covered...

Have you considered....

- > Positioning the EU Legal Representative as an additional safeguard for CTR and GCP adherence and an integral part of the sponsor's compliance?
- > Ensuring rigorous data collection procedures and controls to ensure the generated data's reliability, robustness and integrity?
- $\succ$  Promoting patient involvement and engagement when designing the key elements of clinical protocols?
- $\succ$  Advocating for a risk-based approach rather than a one-size-fits-all?
- $\succ$  Necessitating timely safety reporting, and appropriate risk mitigation strategies throughout the clinical trial lifecycle?
- $\succ$  Transitioning ongoing CTD studies to the CTR, leveraging the expedited review process?
- > Protecting your confidential information and personal data in documents made public under the revised CTR transparency rules?



# Thank you

# How can DLRC help you maximise your products' and company's potential?

### UK

+44 (0)1462 372 472

DLRC Ltd, The Nexus Building, Broadway, Letchworth Garden City, SG6 3TA, UK

### EU

### +49 (0)89 44489 311

Orphix Consulting GmbH, Steinsdorfstraße 19, 80538 Munich, Germany

hello@dlrcgroup.com

www.dlrcgroup.com

Follow DLRC on LinkedIn for the latest regulatory updated & insights

Confidential | DLRC Group



### US

### +1 617 851 1438

DLRC Inc. 1 Broadway, Cambridge, MA 02142



